Wall Street Zen lowered shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) from a hold rating to a sell rating in a report published on Sunday,Wall Street Zen reports.
Several other research analysts also recently commented on QNRX. Weiss Ratings raised shares of Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. BTIG Research started coverage on shares of Quoin Pharmaceuticals in a research note on Monday, October 12th. They set a “buy” rating and a $14.00 price target on the stock. Canaccord Genuity Group started coverage on Quoin Pharmaceuticals in a research note on Monday, October 19th. They issued a “buy” rating and a $18.00 target price for the company. Finally, Lake Street Capital initiated coverage on shares of Quoin Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $20.00 target price on the stock. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.33.
Check Out Our Latest Stock Analysis on Quoin Pharmaceuticals
Quoin Pharmaceuticals Price Performance
Quoin Pharmaceuticals stock opened at $3.70 on Friday. Quoin Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $23.50. The company’s 50 day moving average price is $5.00 and its two-hundred day moving average price is $5.78. The stock has a market cap of $17.76 million, a P/E ratio of -0.19 and a beta of 1.71.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.55. On average, equities analysts anticipate that Quoin Pharmaceuticals will post -7.45 EPS for the current year.
Insider Activity
In other Quoin Pharmaceuticals news, CEO Michael Myers purchased 20,490 shares of the stock in a transaction dated Monday, August 31st. The shares were purchased at an average cost of $4.88 per share, with a total value of $99,991.20. Following the completion of the acquisition, the chief executive officer directly owned 37,713 shares in the company, valued at $184,039.44. This trade represents a 118.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Anthony Culverwell purchased 6,146 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were bought at an average cost of $4.88 per share, for a total transaction of $29,992.48. Following the acquisition, the director owned 40,364 shares in the company, valued at approximately $196,976.32. The trade was a 17.96% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 57,370 shares of company stock valued at $279,966 in the last quarter. Insiders own 7.54% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. SummitTX Capital L.P. increased its stake in Quoin Pharmaceuticals by 54.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after buying an additional 35,505 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in Quoin Pharmaceuticals during the third quarter valued at about $1,077,000. Finally, AIGH Capital Management LLC lifted its position in shares of Quoin Pharmaceuticals by 237.5% in the third quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock valued at $1,077,000 after acquiring an additional 166,234 shares in the last quarter. Institutional investors own 8.63% of the company’s stock.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.
Further Reading
- Five stocks we like better than Quoin Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
